Gilead Sciences, Inc. Smashes Earnings Estimates


Shares of Gilead Sciences slipped by as much as 0.45% in after-hours trading, falling as low as $106.70 per share after tonight’s earnings report

Gilead Sciences released its latest earnings report after closing bell tonight, posting adjusted earnings of $2.43 per share on $7.32 billion in revenue, a 137% year over year increase. Analysts had been expecting earnings of $2.23 per share on $6.72 billion in revenue for the fourth quarter. In the same quarter last year, Gilead posted revenue of $3.12 billion.

Key metrics from Gilead Sciences’ earnings report

Net earnings were $2.18 per share or $3.5 billion, compared to last year’s 47 cents per share or $791 million for the same quarter. Net earnings include acquisition and restructuring costs, among other items.

Joel Greenblatt Owned Hedge Fund On Why Value Investing Isn’t Working Now

Joel GreenblattAcacia Capital was up 12.27% for the second quarter, although it remains in the red for the year because of how difficult the first quarter was. The fund is down 14.25% for the first half of the year. Q2 2020 hedge fund letters, conferences and more Top five holdings Acacia's top five holdings accounted for Read More

For the full year, Gilead Sciences reported sales of $24.5 billion, a 127% year over year increase, and non-GAAP earnings of $8.09 per share, a 297% increase. Net income for the full year was $7.35 per share or $12.1 billion, compared to $3.1 billion or $1.81 per share in 2013.

Gilead Sciences rides high on hepatitis treatments

Gilead Sciences said its fourth quarter sales were driven by its two main hepatitis C drugs, Harvoni and Sovaldi. The drug maker said approximately $3.84 billion of its fourth quarter sales were of those two drugs alone.

Analysts had been concerned about the success of the drugs because of rising competition in the hepatitis C treatment space. They had been projecting sales of $1.5 billion for Harvoni and $2.04 billion for Solvadi, according to MarketWatch‘s Tess Stynes, who cites a note from analyst Mark Schoenebaum of Evercore ISI.

Other product sales amounted to $496 million in the fourth quarter, compared to last year’s $402 million. For the full year, other product sales were $1.7 billion, compared to 2013’s $1.5 billion.

Gilead Sciences provides guidance

For the full 2015 fiscal year, Gilead Sciences projects net product sales of between $26 billion and $27 billion. The drug maker expects a product gross margin of between 87% and 90% and diluted earnings impacts from acquisitions, restructuring and other items of between 82 cents and 87 cents per share.

The company expects to spend between $3 billion and $3.3 billion on research and development during the year.